Housing affordability for new mothers may help stave off postpartum depression

No­var­tis on Tues­day nabbed an­oth­er in­di­ca­tion for its bi­o­log­ic Cosen­tyx (se­cuk­inum­ab), this time in the grow­ing field of treat­ments tar­get­ing the skin con­di­tion hidradeni­tis sup­pu­ra­ti­va

Ob­sid­i­an Ther­a­peu­tics an­nounced Wednes­day that it raised $160.5 mil­lion to push its tu­mor-in­fil­trat­ing lym­pho­cyte (TIL) pro­gram fur­ther in clin­i­cal tri­als. The Se­ries C raise comes